Climb Bio Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Climb Bio.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth28.5%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Sep 23

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Feb 01
Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

Jun 24
We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Mar 08
We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Nov 18
We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Aug 15

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Aug 02

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

Jul 11

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Climb Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqGM:CLYM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024N/A-69-11-11N/A
6/30/2024N/A-6400N/A
3/31/2024N/A-15-7-7N/A
12/31/2023N/A-35-21-21N/A
9/30/2023N/A-39-28-28N/A
6/30/2023N/A-45-36-36N/A
3/31/2023N/A-54-42-42N/A
12/31/2022N/A-45-37-37N/A
9/30/2022N/A-48-37-37N/A
6/30/2022N/A-49-46-46N/A
3/31/2022N/A-46-40-40N/A
12/31/2021N/A-52-36-36N/A
9/30/2021N/A-57-34-34N/A
6/30/2021N/A-49-23-23N/A
3/31/2021N/A-40-19-19N/A
12/31/2020N/A-23-14-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CLYM's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if CLYM's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if CLYM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CLYM's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CLYM's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CLYM's Return on Equity is forecast to be high in 3 years time


Discover growth companies